Refine your search
Collections
Co-Authors
- Anju Kurup
- V. V. Nambiar
- I. Y. Bhatt
- P. A. Deshmukh
- R. R. Jape
- P. N. Jivani
- H. R. Kavale
- S. S. Prakashkar
- Pradnya A. Deshmukh
- Isha Y. Bhatt
- Riddhi R. Jape
- Palak N. Jivani
- Hemangi R. Kavale
- Vandana V. Nambiar
- Sunny S. Prakashkar
- A. Kurup
- R. V. Devkar
- D. S. Dandekar
- B. P. Thakkar
- C. S. Patel
- Khushali Upadhyay
- Foram Patel
- Elizabeth Robin
- Darshee Baxi
- Ansarullah
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Ramachandran, A. V.
- Melatonin and Methoxytryptophol have Temporal Effect on Tail Elongation but not Methoxytryptamine: Studies on Tail Regeneration in Hemidactylus flaviviridis
Abstract Views :243 |
PDF Views:0
Authors
Affiliations
1 Division of Developmental Biology, Department of Zoology, The M. S. University of Baroda, Vadodara – 390002, Gujarat, IN
1 Division of Developmental Biology, Department of Zoology, The M. S. University of Baroda, Vadodara – 390002, Gujarat, IN
Source
Journal of Endocrinology and Reproduction, Vol 14, No 1 (2010), Pagination: 19-24Abstract
In order to evaluate the time-specific influence of pineal indoles on tail regeneration in lizards, melatonin (M), methoxytryptophol (ML) and methoxytryptamine (MT) were administered intraperitonealy to different groups of lizards at morning 7:00 hrs (m) or in the evening at 17:00 hrs (e). The Mm and MLe groups of lizards showed a delay in the attainment of various arbitrary stages of regeneration like wound healing, pre-blastema, blastema and initiation of growth while the Me and MLm groups of lizards showed hastened attainment. However, MTm and MTe treatments did not bring about any difference compared to the controls. The total length of tail regenerated and percentage replacement at the end of 30 days were significantly less in Mm and MLe groups of lizards. MTm and MTe treatments, however, did not affect the regeneration process. The results indicate that M and ML have opposite time-specific effects on regeneration, while MT has no effect. Apparently, M and ML are part of the photoperiodic and neuro-endocrine transduction mechanisms related to regenerative growth in lizards.Keywords
Lizard, Melatonin, Methoxytryptamine, Methoxytryptophol, Regeneration.- Assessment of Extracellular Matrix Remodeling during Tail Regeneration in the Lizard Hemidactylus flaviviridis
Abstract Views :203 |
PDF Views:0
Authors
V. V. Nambiar
1,
I. Y. Bhatt
1,
P. A. Deshmukh
1,
R. R. Jape
1,
P. N. Jivani
1,
H. R. Kavale
1,
S. S. Prakashkar
1,
A. V. Ramachandran
1
Affiliations
1 Division of Developmental and Reproductive Endocrinology, Department of Zoology, The Maharaja Sayajirao University of Baroda, Vadodara - 390 002, IN
1 Division of Developmental and Reproductive Endocrinology, Department of Zoology, The Maharaja Sayajirao University of Baroda, Vadodara - 390 002, IN
Source
Journal of Endocrinology and Reproduction, Vol 12, No 2 (2008), Pagination: 67-72Abstract
Epimorphic regeneration, as exemplified by lizard tail, involves the formation of regeneration blastema as a prerequisite for replacement growth. The formation of blastema is preceded by many regressive changes like tissue demolition, histolysis, inflammation, wound closure, dedifferentiation, cell migration and proliferation. The ECM components of a normal tail help maintain the differentiated state of the constituent heterogeneous tissue and tend to prevent cell migration and proliferation. Since the formation of a regeneration blastema involves many key cellular events like dedifferentiation, migration of dedifferentiated and other nomadic cells and cell proliferation, extensive reorganization of the extracellular matrix is likely to be a major event during post-autotomy period. To this end, total GAG content and gelatinase (MMP-2&9) activity were assayed during the first week post-caudal autotomy. The effect of MMP inhibition by doxycycline was also evaluated in terms of the number of days taken for wound closure and blastema formation as well as the length of detail regenerated at the end of twenty days from the time of initiation of growth. Significant progressive decrement in total GAG content up till 96 hours followed by a significant increment at 120 and 144 hours, together with a biphasic increment in gelatinase activity (first during 24-48 hours and second during 96-144 hours) have been recorded. The increased gelatinase activity and the decreased GAG content in the first 96 hours are suggestive of breakdown of proteoglycans and collagens (type IV, V, VII&X). The second phase of increase in GAG content is related with synthesis of hyaluronate, favoring dedifferentiation, proliferation and migration of cells. MMP inhibition by doxycycline significantly retarded tail regeneration. From these results it is concluded that ECM remodeling is crucial in the immediate post-autotomy period for the formation of an effective blastema and that MMPs play a crucial role in the same.Keywords
ECM Remodeling, GAGs, Lizard, MMPs, Regeneration.- Evaluation of Signaling Molecules in the Post-Autotomy Initiation Phase of Tail Regeneration in the Lizard Hemidactylus flaviviridis
Abstract Views :228 |
PDF Views:0
Authors
Pradnya A. Deshmukh
1,
Isha Y. Bhatt
1,
Riddhi R. Jape
1,
Palak N. Jivani
1,
Hemangi R. Kavale
1,
Vandana V. Nambiar
1,
Sunny S. Prakashkar
1,
A. V. Ramachandran
1
Affiliations
1 Division of Developmental and Reproductive Endocrinology, Department of Zoology, MS University of Baroda, Vadodara - 390 002, IN
1 Division of Developmental and Reproductive Endocrinology, Department of Zoology, MS University of Baroda, Vadodara - 390 002, IN
Source
Journal of Endocrinology and Reproduction, Vol 12, No 1 (2008), Pagination: 31-38Abstract
Epimorphic regeneration, as exemplified by lizard tail, involves the formation of regeneration blastema as a pre-requisite for replacement growth. The formation of blastema is preceded by many regressive changes like tissue demolition, histolysis, inflammation, wound closure, de-differentiation, cell migration and proliferation. Induction of signaling molecules would be crucial in the molecular biology of immediate post-autotomy period in providing the trigger for the initiation of regeneration. It is in this behest that the levels of the cAMP, cGMP and NO have been assayed during the first 72 hr post caudal-autotomy in the lizard Hemidactylus flaviviridis. The influence of exaggerated exogenous induction of NO as well as prolonged action of cGMP by the use of PDE5 inhibitor (sidenafil citrate) have also been evaluated in terms of the number of days taken to complete wound healing and form a blastema as well as the length of tail regenerated at the end of 20 days. cAMP-mediated PKA activation and downstream signaling cascades appear to be the principal mechanism as against cGMP-mediated mechanisms. Controlled NO generation appears to be of pivotal significance in minimizing apoptotic cell loss as substantiated by the reduced caspase 3 activity. Exaggerated induction of NO and prolongation of cGMP action appear to promote apoptotic cell loss resulting in retarded regenerative growth. It can be concluded from the present observations that cAMP- and PKA-mediated events occur first and that minimizing cell apoptosis by controlled NO generation is important in the formation of robust regeneration blastema.Keywords
Apoptosis, Caspase 3, Lizard, Regeneration, Signaling Molecules.- Thyroid Hormone Control of Tail Regeneration: Differential in Loco and Systemic Effects and Seasonal Variation
Abstract Views :249 |
PDF Views:1
Authors
Affiliations
1 Division of Reproductive Endocrinology, Department of Zoology, The Maharaja Sayajirao University of Baroda, Vadodara - 390 002, IN
1 Division of Reproductive Endocrinology, Department of Zoology, The Maharaja Sayajirao University of Baroda, Vadodara - 390 002, IN
Source
Journal of Endocrinology and Reproduction, Vol 10, No 2 (2006), Pagination: 134-142Abstract
Thyroid hormones have been implicated in the control of vertebrate appendage regeneration. In lizards, thyroid hormones have been reported to induce ependymal outgrowth and also exercise control over adaptive systemic metabolic activities. However, there have been no attempts to correlate the seasonal differences in regenerative performance with thyroid activity. The present study has evaluated the effect of induced thyroid hormone excess or deficiency (by T4 administration or methimazole treatment, respectively) on tail regeneration in H. flaviviridis on a seasonal basis in summer, monsoon and winter months. The experiments revealed a retardative influence of hypothyroidism in tail regeneration in both summer and winter months; however blastema formation occurred in the normal time course in the summer months. Hyperthyroidism induced by daily T4 administration, either systemically or in loco, hastened the formation of blastema and provided an early growth spurt but, ultimately, retarded regenerative growth in the summer months. However, T4 administration daily for the first 15 days and every other day thereafter favored a better regenerative growth. In contrast, during the monsoon months, both daily administration and administration every alternate day, either systemically or in loco, delayed blastema formation as well as retarded linear growth. Neither hypothyroidism nor hyperthyroidism exerted any influence on the sluggish performance characteristic of winter months. It is concluded that thyroid activity and thyroid hormone responsiveness vary on a seasonal basis with maximum activity at higher temperatures and minimal at lower temperatures. It can also be concluded that there is differential sensitivity to thyroid hormone during summer and monsoon seasons.Keywords
Regeneration, Tail, Lizard, Thyroid, Season.- Effect of Long Photoperiod (L:D 18:6) on Organ Growth Kinetics, Histology and Serum Profiles of T3, T4, Corticosterone and Progesterone during Post-Hatched Development
Abstract Views :225 |
PDF Views:0
Authors
Affiliations
1 Division of Developmental Biology and Endocrinology : Poultry Section, Department of Zoology, M.S. University of Baroda, Vadodara 390 002, IN
1 Division of Developmental Biology and Endocrinology : Poultry Section, Department of Zoology, M.S. University of Baroda, Vadodara 390 002, IN
Source
Journal of Endocrinology and Reproduction, Vol 2, No 1&2 (1998), Pagination: 34-45Abstract
The pullets of Indian Rhode Island Red (RIR) breed of domestic fowl were reared under a step-down photoperiod of LD 18:6 (long photoperiod; LP) from day 1 to day 90 post-hatch, and then shifted to LD 12:12 (NLD), to assess its effect on growth kinetics of lymphoid and reproductive organs, and serum hormone profiles, the observations were made at 30,60 and 90 days and the results were compared with pullets reared under NLD alone. The weights of thyroid and ovary in LP chicks showed significant increment, whereas the weights of liver and lymphoid organs were identical to that of NLD chicks. The weights of adrenal and oviduct decreased significantly. In general, serum levels of T3, T4, corticosterone and progesterone tended to show a gradual decrement with age in NLD chicks, but the LP chicks showed a differential change marked by high T3 and T4 levels throughout and, increased corticosterone and decreased progesterone levels at 30 and 60 days. Long photoperiod seems to have an initial depressive, but later stimulatory effect on growth of thyroid, while it has an Inhibitory effect on adrenal. The histometric data of ovary suggest a stimulatory effect of light, indicated by increased number of follicles and decreased degree of follicular atresia. It is concluded from the present observations that exposure of chicks to LP has differential effects on growth kinetics and, a favourable influence on reproductive hormones suggesting inherent photosensitivity and, no setting in of photorefractoriness during this period.Keywords
Chick Ovary, Corticosterone, Growth Kinetics, Lymphoid Organs, Photoperiod, Progesterone, Thyroid Hormones.- Neonatal Exposure to Melatonin Favours Follicular Survival and Increases Fecundity in the Female Rat
Abstract Views :185 |
PDF Views:0
Authors
Affiliations
1 Division of Reproductive Biology and Endocrinology, Department of Zoology, M. S. University of Baroda, Vadodara Gujarat, IN
1 Division of Reproductive Biology and Endocrinology, Department of Zoology, M. S. University of Baroda, Vadodara Gujarat, IN
Source
Journal of Endocrinology and Reproduction, Vol 9, No 1&2 (2005), Pagination: 43-50Abstract
Rat neonates have been exposed to melatonin by i.p. injection of 40(19 melatonin/animal/day daily in the evening at 16:30 hrs from day 0 to day 21. The preweaning hypeimelatonemia did not significantly influence either adult body weight or ovarian weight. The estrogen titre was reduced and progesterone titre increased in melatonin treated rats. Increased thyroid weight and elevated thyroid hormones levels were also recorded. The primordial and primary follicles were more in number with significantly lesser atretic follicles of all developmental stages. The first litter size was significantly greater (lit 3 vs 8 ± 2) in melatonin treated rats compared to controls. These results are interpreted in terms of protective action of neonatal melatonin against follicular apoptosis either directly or indirectly through thyroid hormones.Keywords
Follicular Apoptosis, Melatonin, Progesterone, Thyroid Hormone.- Alterations in Carbohydrate Metabolism and Pancreatic Islet Functions in Pigeons Treated with Pineal Indoles and PCPA
Abstract Views :239 |
PDF Views:0
Authors
Affiliations
1 Zoology Division, Department of Biology, Bahuddin Science College, Junagadh, Gujarat, IN
2 Division of Avian Endocrinology, Department of Zoology, M.S. University of Baroda, Vadodara 390 002, IN
1 Zoology Division, Department of Biology, Bahuddin Science College, Junagadh, Gujarat, IN
2 Division of Avian Endocrinology, Department of Zoology, M.S. University of Baroda, Vadodara 390 002, IN
Source
Journal of Endocrinology and Reproduction, Vol 7, No 1&2 (2003), Pagination: 41-41Abstract
Possible impact of pineal indoles (Melatonin-M; Methoxytryptophol-ML; Methoxytryptamine-MT) and pCPA on carbohydrate metabolism in terms of hepatic and muscle glycogen contents, hepatic phosphorylase and G-6-Pase on blood glucose level and pancreatic islet functions have been studied in the feral pigeons, Columba livia during the recrudescent phase.- Breaching the Barriers of Chemotherapeutics for Breast Cancer with Alternative Medicine
Abstract Views :372 |
PDF Views:0
Authors
Affiliations
1 Division of Biomedical and Life-Science, School of Science, Navrachana University, Vadodara − 391410, Gujarat, IN
2 School of Science, Navrachana University, Vadodara − 391410, Gujarat, IN
1 Division of Biomedical and Life-Science, School of Science, Navrachana University, Vadodara − 391410, Gujarat, IN
2 School of Science, Navrachana University, Vadodara − 391410, Gujarat, IN
Source
Journal of Endocrinology and Reproduction, Vol 25, No 1 (2021), Pagination: 23-35Abstract
Breast cancer is one of the most prevalent forms of cancers in women around the world. Owing to its biochemical variation and complexity, treatment with chemotherapy and/or radiotherapy is very complicated and often results in adverse side effects. This article reviews the widely practiced chemotherapeutic drugs, their modes of actions and side effects. The several breast cancer therapeutic approaches based on medicinal plants, hormones, nutritional supplements and/or some advanced drug delivery systems that may lead to faster recovery are also reviewed.Keywords
Alternative Therapy, Breast Cancer Therapy, Chemotherapeutics.References
- Breast Cancer. 2018. https://www.who.int/cancer/ prevention/diagnosis-screening/breast-cancer/en/.
- Lacey JV, Kreimer AR, Buys SS et al. Breast cancer epidemiology according to recognized breast cancer risk factors in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial Cohort. BMC Cancer, 2009; 9:84. https://doi.org/10.1186/1471-2407-9-8. PMid:19134206 PMCid:PMC2645422.
- Danaei G, Vander Hoorn S, Lopez AD et al. Causes of cancer in the world: Comparative risk assessment of nine behavioural and environmental risk factors. The Lancet. 2005; 366(9499):1784-1793. https://doi.org/10.1016/ S0140-6736(05)67725-2.
- Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000; 100(1):57-70. https://doi.org/10.1016/S0092- 8674(00)81683-9.
- Suter R, Marcum JA. The molecular genetics of breast cancer and targeted therapy. Biologics. 2007; 1(3):241-258.
- Schneeweiss A, Ruckhäberle E, Huober J. Chemotherapy for metastatic breast cancer-an anachronism in the era of personalised and targeted oncological therapy? Geburtshilfe Frauenheilkunde. 2015; 75(6):574-583. https://doi.org/10.1055/s-0035-1546150. PMid:26166838 PMCid:PMC4490921.
- Rouzier R, Perou CM, Symmans WF et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clinical Cancer Research. 2005; 11(16):5678-5685. https://doi.org/10.1158/1078-0432. CCR-04-2421.PMid:16115903.
- Gegechkori N, Haines L, Lin JJ. Long-term and latent side effects of specific cancer types. Medical Clinics. 2017; 101(6):1053-1073. https://doi.org/10.1016/j. mcna.2017.06.003. PMid:28992854 PMCid:PMC5777532.
- Fojo T, Menefee M. Mechanisms of multidrug resistance: the potential role of microtubule-stabilizing agents. Annals of Oncology. 2007; 18:v3-v8. https://doi.org/10.1093/ annonc/mdm172. PMid:17656560.
- Kamath K, Wilson L, Cabral F, Jordan MA. βIII-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability. Journal of Biological Chemistry. 2005; 280(13):12902-12907. https:// doi.org/10.1074/jbc.M414477200. PMid:15695826.
- Paradiso A, Mangia A, Chiriatti A, et al. Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer. Annals of Oncology. 2005; 16:iv14-iv19. https://doi.org/10.1093/annonc/mdi902. PMid:15923415.
- Tommasi S, Mangia A, Lacalamita R et al. Cytoskeleton and paclitaxel sensitivity in breast cancer: The role of β‐tubulins. International Journal of Cancer. 2007; 120(10):2078-2085. https://doi.org/10.1002/ijc.22557. PMid:17285590.
- Thorn CF, Oshiro C, Marsh S et al. Doxorubicin pathways: Pharmacodynamics and adverse effects. Pharmacogenetics and Genomics. 2011; 21(7):440-446. https://doi. org/10.1097/FPC.0b013e32833ffb56. PMid:21048526 PMCid:PMC3116111.
- Lao J, Madani J, Puértolas T et al. Liposomal doxorubicin in the treatment of breast cancer patients: A review. Journal of Drug Delivery. 2013. https://doi.org/10.1155/2013/456409. PMid:23634302 PMCid:PMC3619536.
- Aggarwal S, Verma SS, Aggarwal S, Gupta SC. Drug Repurposing for Breast Cancer Therapy: Old Weapon for New Battle. In: Seminars in Cancer Biology. Academic Press; 2021. 68, p. 8-10. https://doi. org/10.1016/j.semcancer.2019.09.012. PMid:31550502 PMCid:PMC7128772.
- Weaver BA. How taxol/paclitaxel kills cancer cells. Molecular Biology of the Cell. 2014; 25(18): 2677-2681. https://doi.org/10.1091/mbc.e14-04-0916. PMid:25213191 PMCid:PMC4161504.
- Abulkhair O, El Melou, W. Delayed paclitaxeltrastuzumab- induced interstitial pneumonitis in breast cancer. Case Reports in Oncology. 2011; 4(1):186-191. https://doi.org/10.1159/000326063. PMid:21516267 PMCid:PMC3080783.
- Miele E, Spinelli GP, Miele E et al. Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer. International Journal of Nanomedicine. 2009; 4:99-105. https://doi.org/10.2147/ IJN.S3061. PMid:19516888 PMCid:PMC2720743.
- Herbst RS, Khuri FR. Mode of action of docetaxel-a basis for combination with novel anti-cancer agents. Cancer Treatment Reviews. 2003; 29(5):407-415. https://doi. org/10.1016/S0305-7372(03)00097-5.
- Ho MY, Mackey JR. Presentation and management of docetaxel-related adverse effects in patients with breast cancer. Cancer Management and Research. 2014; 6:253-259. https://doi.org/10.2147/CMAR.S40601. PMid:24904223 PMCid:PMC4041377.
- Moore YA. Clinical applications for topical 5-fluorouracil in the treatment of dermatological disorders. Journal of Dermatological Treatment. 2009; 20(6):328-335. https:// doi.org/10.3109/09546630902789326. PMid:19954388.
- Nabholtz JM, Cantin J, Chang J et al. Phase III trial comparing granulocyte colony-stimulating factor to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel/doxorubicin/ cyclophosphamide: Results of the BCIRG 004 trial. Clinical Breast Cancer. 2002; 3(4):268-275. https://doi.org/10.3816/ CBC.2002.n.030. PMid:12425755.
- De Jonge ME, Huitema AD, Rodenhuis S, Beijnen JH. Clinical pharmacokinetics of cyclophosphamide. Clinical Pharmacokinetics. 2005; 44(11):1135-1164. https://doi. org/10.2165/00003088-200544110-00003. PMid:16231966.
- Zeng F, Ju RJ, Liu L et al. Application of functional vincristine plus dasatinib liposomes to deletion of vasculogenic mimicry channels in triple-negative breast cancer. Oncotarget. 2015; 6(34):36625-36642. https:// doi.org/10.18632/oncotarget.5382. PMid:26429872 PMCid:PMC4742200.
- Radford JA, Knight RK, Rubens RD. (1985). Mitomycin C and vinblastine in the treatment of advanced breast cancer. European Journal of Cancer and Clinical Oncology. 1985; 21(12):1475-1477. https://doi.org/10.1016/0277- 5379(85)90241-X.
- Cybulska-StopaB, Ziobro M, Skoczek M et al. Evaluation of vinorelbine-based chemotherapy as the second or further-line treatment in patients with metastatic breast cancer. Contemporary Oncology. 2013; 17(1):78-82. https://doi.org/10.5114/wo.2013.33779. PMid:23788967 PMCid:PMC3685356.
- Siddik ZH. Cisplatin: Mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003; 22(47):7265-7279. https://doi.org/10.1038/sj.onc.1206933. PMid:14576837.
- Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. European Journal of Pharmacology. 2014; 740:364-378. https://doi. org/10.1016/j.ejphar.2014.07.025. PMid:25058905 PMCid: PMC4146684.
- Von Minckwitz G, Schneeweiss A, Loibl S et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): A randomised phase 2 trial. The Lancet Oncology. 2014; 15(7):747-756. https://doi.org/10.1016/S1470- 2045(14)70160-3.
- Smorenburg CH, Bontenbal M, Verweij J. Capecitabine in breast cancer: Current status. Clinical Breast Cancer. 2001; 1(4):288-293. https://doi.org/10.3816/CBC.2001.n.003. PMid:11899351.
- Vogelstein B, Papadopoulos N, Velculescu VE et al. Cancer genome landscapes. Science. 2013; 339(6127):1546-1558. https://doi.org/10.1126/science.1235122. PMid:23539594 PMCid:PMC3749880.
- Greenwell M, Rahman PKSM. Medicinal plants: Their use in anticancer treatment. International Journal of Pharmaceutical Sciences and Research. 2015; 6(10):4103- 4112.
- Steigerová J, Oklešťková J, Levková M, Rárová L, Kolář Z, Strnad M. Brassinosteroids cause cell cycle arrest and apoptosis of human breast cancer cells. Chemicobiological Interactions. 2010: 188(3):487-496. https://doi. org/10.1016/j.cbi.2010.09.006. PMid:20833159.
- Yin SY, Wei WC, Jian FY, Yang NS. Therapeutic applications of herbal medicines for cancer patients. Evidence-Based Complementary and Alternative Medicine. 2013. https://doi.org/10.1155/2013/302426. https://doi.org/10.1155/2013/302426. PMid:23956768 PMCid:PMC3727181.
- Thangapazham RL, Singh AK, Sharma A et al. Green tea polyphenols and its constituent epigallocatechin gallate inhibits proliferation of human breast cancer cells in vitro and in vivo. Cancer Letters. 2007; 245(1-2):232-241. https:// doi.org/10.1016/j.canlet.2006.01.027. PMid:16519995,
- Biswal BM, Sulaiman SA, Ismail HC et al. Effect of Withania somnifera (Ashwagandha) on the development of chemotherapy-induced fatigue and quality of life in breast cancer patients. Integrative Cancer Therapies. 2013; 12(4):312-322. https://doi.org/10.1177/1534735412464551. PMid:23142798.
- Rossi RE, Pericleous M, Mandair D, Whyand T, Caplin ME. The role of dietary factors in prevention and progression of breast cancer. Anticancer Research. 2014; 34(12):6861- 6875.
- Sanchez-Barcelo EJ, Mediavilla MD, Alonso-Gonzalez C, Reiter RJ. Melatonin uses in oncology: breast cancer prevention and reduction of the side effects of chemotherapy and radiation. Expert Opinion on Investigational Drugs. 2012; 21(6):819-831. https://doi.org/10.1517/13543784.20 12.681045. PMid:22500582.
- Goncalves NDN, Colombo J, Lopes JR et al. Effect of melatonin in epithelial mesenchymal transition markers and invasive properties of breast cancer stem cells of canine and human cell lines. PloS One. 2016; 11(3):e0150407. doi: 10.1371/journal.pone.0150407. https://doi.org/10.1371/ journal.pone.0150407. PMid:26934679 PMCid:PMC 4774906.
- Jardim-Perassi B, Lourenço MR, Doho GM et al. Melatonin regulates angiogenic factors under hypoxia in breast cancer cell lines. Anti-Cancer Agents in Medicinal Chemistry. 2016; 16(3):347-358. https://doi.org/10.2174/18715206156 66150511094201. PMid:25963143.
- Alvarez‐García V, González A, Alonso‐González C et al. Regulation of vascular endothelial growth factor by melatonin in human breast cancer cells. Journal of Pineal Research. 2013; 54(4):373-380. https://doi.org/10.1111/ jpi.12007. PMid:23013414.
- Pires de Campos Zuccari D, Jardim BV, Lope, JR et al. Evaluation of hypoxia inducible factor 1-alpha (HIF1A) after treatment with melatonin in breast cancer cell line. European Journal of Cancer. 2012; 48:S254-S255. https:// doi.org/10.1016/S0959-8049(12)71665-9.
- Rosanò L, Spinella F, Bagnato A. Endothelin 1 in cancer: biological implications and therapeutic opportunities. Nature Reviews Cancer. 2013; 13(9):637-651. https://doi. org/10.1038/nrc3546. PMid:23884378.
- Demaria S, Pikarsky E, Karin M et al. Cancer and inflammation: promise for biological therapy. Journal of Immunotherapy. 2010; 33(4):335-351. https://doi. org/10.1097/CJI.0b013e3181d32e74. PMid:20386472 PMCid:PMC2941912.
- Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008; 454(7203):436-444. https:// doi.org/10.1038/nature07205. PMid:18650914.
- Woo SM, Min KJ, Kwon TK. Melatonin‐mediated Bim up‐regulation and cyclooxygenase‐2 (COX‐2) downregulation enhances tunicamycin‐induced apoptosis in MDA‐MB‐231 cells. Journal of Pineal Research. 2015; 58(3):310-320. https://doi.org/10.1111/jpi.12217. PMid:25711465.
- Zhang SL, Chen TS, Ma CY et al. Effect of vitamin B supplementation on cancer incidence, death due to cancer, and total mortality: A PRISMA-compliant cumulative meta-analysis of randomized controlled trials. Medicine. 2016; 95(31):e3485. https://doi. org/10.1097/MD.0000000000003485. PMid:27495015 PMCid:PMC4979769.
- Wu W, Kang S, Zhang D. Association of vitamin B 6, vitamin B 12 and methionine with risk of breast cancer: A doseresponse meta-analysis. British Journal of Cancer. 2013; 109(7):1926-1944. https://doi.org/10.1038/bjc.2013.438. PMid:23907430 PMCid:PMC3790153.
- Ullah MF, Khan HY, Zubair H et al. The antioxidant ascorbic acid mobilizes nuclear copper leading to a prooxidant breakage of cellular DNA: Implications for chemotherapeutic action against cancer. Cancer Chemotherapy and Pharmacology. 2011; 67(1):103- 110. https://doi.org/10.1007/s00280-010-1290-4. PMid: 20213077.
- Codini M. Why Vitamin C could be an excellent complementary remedy to conventional therapies for breast cancer. International Journal of Molecular Sciences. 2020; 21(21):8397. doi: 10.3390/ijms21218397. https://doi.org/10.3390/ijms21218397. PMid:33182353 PMCid:PMC7664876.
- Bober P, Alexovic M, Talian I et al. Proteomic analysis of the vitamin C effect on the doxorubicin cytotoxicity in the MCF-7 breast cancer cell line. Journal of Cancer Research and Clinical Oncology. 2017; 143(1):35-42. https://doi. org/10.1007/s00432-016-2259-4. PMid:27620743.
- Hong SW, Lee SH, Moon JH et al. SVCT-2 in breast cancer acts as an indicator for L-ascorbate treatment. Oncogene. 2013; 32(12):1508-1517. https://doi.org/10.1038/ onc.2012.176. PMid:22665050.
- Hatem E, Azzi S, El Banna N et al. Auranofin/vitamin C: A novel drug combination targeting triple-negative breast cancer. Journal of the National Cancer Institute. 2019; 111(6):597-608. https://doi.org/10.1093/jnci/djy149. PMid:30779852.
- Zeng LH, Wang QM, Feng LY et al. High-dose vitamin C suppresses the invasion and metastasis of breast cancer cells via inhibiting epithelial-mesenchymal transition. Onco Targets and Therapy. 2019; 12, 7405-7413. https://doi.org/10.2147/OTT.S222702. PMid:31571901 PMCid:PMC6753468.
- Evans RM. The steroid and thyroid hormone receptor superfamily. Science. 1988; 240(4854):889-895. https:// doi.org/10.1126/science.3283939. PMid:3283939 PMCid: PMC6159881.
- Carlber C. Current understanding of the function of the nuclear vitamin D receptor in response to its natural and synthetic ligands. Recect Results in Cancer Research. 2003; 164:29-42. https://doi.org/10.1007/978-3-642-55580-0_2. PMid:12899512.
- Shao T, Klein P, Grossbard ML. Vitamin D and breast cancer. The Oncologist. 2012; 17(1):36-45. https://doi. org/10.1634/theoncologist.2011-0278. PMid:22234628 PMCid:PMC3267821.
- Kumar SR, Priyatharshni S, Babu VN et al. Quercetin conjugated superparamagnetic magnetite nanoparticles for in-vitro analysis of breast cancer cell lines for chemotherapy applications. Journal of Colloid and Interface Science. 2014; 436:234-242. https://doi.org/10.1016/j.jcis.2014.08.064. PMid:25278361.
- Denkert C, von Minckwitz G, Darb-Esfahani S et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: A pooled analysis of 3771 patients treated with neoadjuvant therapy. The Lancet Oncology. 2018; 19(1):40-50. https://doi.org/10.1016/ S1470-2045(17)30904-X.
- Keenan TE, Tolaney SM. Role of immunotherapy in triple-negative breast cancer. Journal of the National Comprehensive Cancer Network. 2020; 18(4):479-489. https://doi.org/10.6004/jnccn.2020.7554. PMid:32259782.
- Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018; 359(6382):1350-1355. https://doi.org/10.1126/science.aar4060. PMid:29567705 PMCid:PMC7391259.
- Mendell JT. Targeting a long noncoding RNA in breast cancer. New England Journal of Medicine. 2016; 374(23):2287-2289. https://doi.org/10.1056/ NEJMcibr1603785. PMid:27276568.
- Jin X, Xu X E, Jiang YZ et al. The endogenous retrovirusderived long noncoding RNA TROJAN promotes triple-negative breast cancer progression via ZMYND8 degradation. Science Advances. 2019; 5(3):eaat9820. https://doi.org/10.1126/sciadv.aat9820. PMid:30854423 PMCid:PMC6402854
- Tchou J, Zhao Y, Levine BL et al. Safety and efficacy of intratumoral injections of Chimeric Antigen Receptor (CAR) T cells in metastatic breast cancer. Cancer Immunology Research. 2017; 5(12):1152-1161. https:// doi.org/10.1158/2326-6066.CIR-17-0189. PMid:29109077 PMCid:PMC5712264.
- Pancreatic β-Cell Dysfunction in Diabetes
Abstract Views :72 |
PDF Views:0
Authors
Affiliations
1 The Jackson Laboratory, Bar Harbor, 04609, Maine, US
2 School of Science, Navrachana University, Vadodara 391410, Gujarat, IN
1 The Jackson Laboratory, Bar Harbor, 04609, Maine, US
2 School of Science, Navrachana University, Vadodara 391410, Gujarat, IN
Source
Journal of Endocrinology and Reproduction, Vol 26, No 4 (2022), Pagination: 207-212Abstract
The decline in functional β-cell mass and β-cell dysfunction causes diabetes. Pancreatic β-cells play a fundamental role in controlling the glucose milieu, and β-cells of diabetic patients poorly respond to glucose. The mechanism underlying the pathology of impaired β-cell function is a unique challenge. This concise review summarizes the identity of β-cells during the progression and established diabetes. Understanding β-cell heterogeneity and the dynamic functional state during health and disease progression would be important for designing diabetes therapeutics to restore the β-cell mass by cellreplacement or regeneration approaches.Keywords
β-Cell Dedifferentiation, β-Cell Dysfunction, β-Cell Identity.References
- Gemmill CL. The Greek concept of diabetes. Bull N Y Acad Med. 1972; 48(8):1033-6.
- Hegele RA, Maltman GM. Insulin’s centenary: the birth of an idea. Lancet Diabetes Endocrinol. 2020; 8(12):971-7. https://doi.org/10.1016/S2213-8587(20)30337-5 PMID:33129375
- Sun H, Saeedi P, Karuranga S, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022; 183:109119. https://doi.org/10.1016/j.diabres.2021.109119 PMID:34879977
- Butler AE, Janson J, Bonner-Weir S, et al. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes. 2003; 52(1):102-10. https://doi.org/10.2337/diabetes.52.1.102 PMID:12502499
- Ali O. Genetics of type 2 diabetes. World J Diabetes. 2013; 4(4):114-23. https://doi.org/10.4239/wjd.v4.i4.114 PMID:23961321 PMCID:PMC3746083
- Wang W, Zhang C. Targeting β-cell dedifferentiation and transdifferentiation: Opportunities and challenges. Endocrine Connections. BioScientifica Ltd. 2021; p. R213-28. https://doi.org/10.1530/EC-21-0260 PMID:34289444 PMCID:PMC8428079
- Jermendy A, Toschi E, Aye T, et al. Rat neonatal beta cells lack the specialised metabolic phenotype of mature beta cells. Diabetologia. 2011; 54(3):594-604. https://doi.org/10.1007/s00125-010-2036-x PMID:21240476 PMCID:PMC3045081
- Bensellam M, Jonas JC, Laybutt DR. Mechanisms of β;-cell dedifferentiation in diabetes: Recent findings and future research directions. Journal of Endocrinology. BioScientifica Ltd. 2018; p. R109-43. https://doi.org/10.1530/JOE-17-0516 PMID:29203573
- Diedisheim M, Oshima M, Albagli O, et al. Modeling human pancreatic beta cell dedifferentiation. Mol Metab. 2018; 10:74-86. https://doi.org/10.1016/j.molmet.2018.02.002 PMID:29472102 PMCID:PMC5985229
- Talchai C, Xuan S, Lin HV, et al. Pancreatic β cell dedifferentiation as a mechanism of diabetic β cell failure. Cell. 2012; 150(6):1223-34. https://doi.org/10.1016/j.cell.2012.07.029 PMID:22980982 PMCID:PMC3445031
- Sachs S, Bastidas-Ponce A, Tritschler S, et al. Targeted pharmacological therapy restores β-cell function for diabetes remission. Nat Metab. 2020; 2(2):192-209. https://doi.org/10.1038/s42255-020-0171-3 PMID:32694693
- Dore BA, Grogan WM, Madge GE, et al. Biphasic development of the postnatal mouse pancreas. Biol Neonate. 1981; 40(5-6):209-17. https://doi.org/10.1159/000241494 PMID:7032613
- Blum B, Hrvatin S, Schuetz C, et al. Functional beta-cell maturation is marked by an increased glucose threshold and by expression of urocortin 3. Nat Biotechnol. 2012; 30(3):261-4. https://doi.org/10.1038/nbt.2141 PMID:22371083 PMCID:PMC4617627
- Jacovetti C, Matkovich SJ, Rodriguez-Trejo A, et al. Postnatal β-cell maturation is associated with islet-specific microRNA changes induced by nutrient shifts at weaning. Nat Commun. 2015; 6:8084. https://doi.org/10.1038/ncomms9084 PMID:26330140 PMCID:PMC4569696 15. Brunzell JD, Robertson RP, Lerner RL, et al. Relationships between fasting plasma glucose levels and insulin secretion during intravenous glucose tolerance tests. The Journal of Clinical Endocrinology and Metabolism. 1976; 42(2):222-9. https://doi.org/10.1210/jcem-42-2-222 PMID:1262429
- Weyer C, Bogardus C, Mott DM, et al. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest. 1999; 104(6):787-94. https://doi.org/10.1172/JCI7231 PMID:10491414 PMCID:PMC408438
- van Haeften TW, Pimenta W, Mitrakou A, et al. Relative conributions of beta-cell function and tissue insulin sensitivity to fasting and postglucose-load glycemia. Metabolism. 2000; 49(10):1318-25. https://doi.org/10.1053/meta.2000.9526 PMID:11079822
- White MG, Marshall HL, Rigby R, et al. Expression of mesenchymal and α-cell phenotypic markers in islet β-cells in recently diagnosed diabetes. Diabetes Care. 2013; 36(11):3818-20. https://doi.org/10.2337/dc13-0705 PMID:24062329 PMCID:PMC3816907
- Marselli L, Suleiman M, Masini M, et al. Are we overestimating the loss of beta cells in type 2 diabetes? Diabetologia. 2014; 57(2):362-5. https://doi.org/10.1007/s00125-013-3098-3 PMID:24233056
- Moin ASM, Butler AE. Alterations in Beta Cell Identity in Type 1 and Type 2 Diabetes. Curr Diab Rep. 2019; 19(9):83. https://doi.org/10.1007/s11892-019-1194-6 PMID:31401713 PMCID:PMC6689286
- Rutter GA, Pullen TJ, Hodson DJ, et al. Pancreatic β-cell identity, glucose sensing and the control of insulin secretion. Biochem J. 2015; 466(2):203-18. https://doi.org/10.1042/BJ20141384 PMID:25697093
- Salinno C, Buttner M, Cota P, et al. CD81 marks immature and dedifferentiated pancreatic β-cells. Mol Metab. 2021; 49:101188. https://doi.org/10.1016/j.molmet.2021.101188 PMID:33582383 PMCID:PMC7932895
- Salinno C, Cota P, Bastidas-Ponce A, et al. β-Cell Maturation and Identity in Health and Disease. Int J Mol Sci. 2019; 20(21). https://doi.org/10.3390/ijms20215417 PMID:31671683 PMCID:PMC6861993
- Casteels T, Zhang Y, Frogne T, et al. An inhibitor-mediated beta-cell dedifferentiation model reveals distinct roles for FoxO1 in glucagon repression and insulin maturation. Mol Metab. 2021; 54. https://doi.org/10.1016/j.molmet.2021.101329 PMID:34454092 PMCID:PMC8476777
- Wang Z, York NW, Nichols CG, et al. Pancreatic β cell dedifferentiation in diabetes and redifferentiation following insulin therapy. Cell Metab. 2014; 19(5):872-82. https://doi.org/10.1016/j.cmet.2014.03.010 PMID:24746806 PMCID:PMC4067979
- Laybutt DR, Sharma A, Sgroi DC, et al. Genetic regulation of metabolic pathways in beta-cells disrupted by hyperglycemia. J Biol Chem. 2002; 277(13):10912-21. https://doi.org/10.1074/jbc.M111751200 PMID:11782487
- Jonas JC, Sharma A, Hasenkamp W, et al. Chronic hyperglycemia triggers loss of pancreatic beta cell differentiation in an animal model of diabetes. J Biol Chem. 1999; 274(20):14112-21. https://doi.org/10.1074/jbc.274.20.14112 PMID:10318828
- Dahan T, Ziv O, Horwitz E, et al. Pancreatic β-Cells Express the Fetal Islet Hormone Gastrin in Rodent and Human Diabetes. Diabetes. 2017; 66(2):426-36. https://doi.org/10.2337/db16-0641 PMID:27864307 PMCID:PMC5248995
- Cinti F, Bouchi R, Kim-Muller JY, et al. Evidence of β-Cell Dedifferentiation in Human Type 2 Diabetes. J Clin Endocrinol Metab. 2016; 101(3):1044-54. https://doi.org/10.1210/jc.2015-2860 PMID:26713822 PMCID:PMC4803182
- Tchkonia T, Zhu Y, van Deursen J, et al. Cellular senescence and the senescent secretory phenotype: therapeutic opportunities. J Clin Invest. 2013; 123(3):966-72. https://doi.org/10.1172/JCI64098 PMID:23454759 PMCID:PMC3582125
- He S, Sharpless NE. Senescence in Health and Disease. Cell. 2017; 169(6):1000-11. https://doi.org/10.1016/j.cell.2017.05.015 PMID:28575665 PMCID:PMC5643029
- Casteels T, Zhang Y, Frogne T, et al. An inhibitor-mediated beta-cell dedifferentiation model reveals distinct roles for FoxO1 in glucagon repression and insulin maturation. Mol Metab. 2021; 54:101329. https://doi.org/10.1016/j.molmet.2021.101329 PMID:34454092 PMCID:PMC8476777
- Oppenlander L, Palit S, Stemmer K, et al. Vertical sleeve gastrectomy triggers fast β-cell recovery upon overt diabetes. Mol Metab. 2021; 54:101330. https://doi.org/10.1016/j.molmet.2021.101330 PMID:34500108 PMCID:PMC8487975
- Jain, C., Ansarullah, Bilekova, S. et al. Targeting pancreatic β cells for diabetes treatment. Nat Metab. 2022; 4:1097-1108. https://doi.org/10.1038/s42255-022-00618-5 PMID:36131204